Aussie cancer diagnosis firm expands with $3.3b merger Telix Pharmaceuticals will acquire a German radioisotope manufacturer, giving it greater control of its isotope supply it is using in cancer treatment. AAP · Sep 21
Brain Cancer Patients Gain First Approved PET Drug for Separating Tumor Regrowth From Treatment Related Change The FDA has approved Pixclara, the first PET imaging drug for glioma, to help separate tumor regrowth from treatment-related change. Medical Daily · Sep 14
Aussie imaging agent to help brain cancer patients The United States Food and Drug Administration has approved Telix Pharmaceutical's Pixclara, an imaging agent to aid in the diagnosis of brain cancer. AAP · Sep 14
Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and how theranostics may help address these. David N. Cade, MD, Telix Group Chief Medical Officer... AAP · Jun 22
CSL, Mayne Pharma expect to dodge new US pharma tariffs Both CSL and Adelaide-based woman's health company Mayne Pharma say they won't be impacted by Donald Trump's new pharmaceutical tariffs. AAP · Apr 7
Telix Pharmaceuticals Enters Q4 On Strong Footing With Stabilized Pricing Pressures, Upgraded Annual Sales Guidance Telix Pharmaceuticals (NASDAQ:TLX) updated on Tuesday its commercial and operational performance for the third quarter of fiscal 2025. Benzinga · Oct 14, 2025
Telix Gets Second FDA Rejection For Kidney Cancer Drug On Thursday, Telix Pharmaceuticals Limited (NASDAQ:TLX) received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for TLX250-CDx (Zircaix, 89Zr-DFO girentuximab), an investigational PET2 agent for the diagnosis and characterization of renal masses as clear cell renal cell carcinoma (ccRCC). Benzinga · Aug 28, 2025
Telix Pharmaceuticals Trial Enter Critical Stage, Analyst Predicts Big Gains Telix Pharmaceuticals Ltd (NASDAQ:TLX) is the world's most "diversified, comprehensively positioned, and standalone publicly-traded radiopharmaceuticals company," according to HC Wainwright. Benzinga · Jul 3, 2025
Aussie shares dip slightly, ending 10-day win streak The ASX200 has finished three points lower, just enough to snap its longest winning streak since early-2015. AAP · Aug 23, 2024
Telix posts first profit as sales triple to $502m Melbourne-based radiation oncology business Telix Pharmaceuticals has made its first-ever profit after strong sales for its prostate cancer imaging agent. AAP · Feb 23, 2024
Aussie biomedical innovations will revolutionise the lives of quadriplegics and cancer patients Australian companies have made significant progress in biomedical technologies to bring new remedies to people who need them most. The New Daily · Mar 27, 2023
Australian biotech developments can give independence to quadriplegics Australian companies are making significant strides in biomedical technologies that deliver remedies in new ways The New Daily · Sep 22, 2022